How can attrition rates be reduced in cancer drug discovery?

JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer

(2012) Adrian Britschgi et al.   CANCER CELL

Accelerating Cancer Therapy Development: The Importance of Combination Strategies and Collaboration. Summary of an Institute of Medicine Workshop

(2012) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Improving Publication Rates of Biomarker Results from Cancer Trials

(2012) R. Iannone   CLINICAL CANCER RESEARCH

Publication and Reporting Conduct for Pharmacodynamic Analyses of Tumor Tissue in Early-Phase Oncology Trials

(2012) G. A. Freeman et al.   CLINICAL CANCER RESEARCH

Heterogeneity of Epidermal Growth Factor Receptor Status and Mutations of KRAS/PIK3CA in Circulating Tumor Cells of Patients with Colorectal Cancer

(2012) C. Gasch et al.   CLINICAL CHEMISTRY

A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer

(2012) J. Rodríguez-Pascual et al.   INVESTIGATIONAL NEW DRUGS

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns

(2012) A S Moore et al.   LEUKEMIA

Diagnosing the decline in pharmaceutical R&D efficiency

(2012) Jack W. Scannell et al.   NATURE REVIEWS DRUG DISCOVERY

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification

(2012) L. J. Valentijn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Valley of Death in anticancer drug development: a reassessment

(2012) David J. Adams   TRENDS IN PHARMACOLOGICAL SCIENCES

Medicines for pediatric oncology: can we overcome the failure to deliver?

(2012) Agnes Saint-Raymond et al.   Expert Review of Clinical Pharmacology

Applicability of a "Pick a Winner" trial design to acute myeloid leukemia

(2011) R. K. Hills et al.   BLOOD

Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR

(2011) Areti Strati et al.   BMC CANCER

Targeting IGF-1R: throwing out the baby with the bathwater?

(2011) B Basu et al.   BRITISH JOURNAL OF CANCER

Targeted agents: How to select the winners in preclinical and early clinical studies?

(2011) Rachel Goodwin et al.   EUROPEAN JOURNAL OF CANCER

NCATS Could Mitigate Pharma Valley of Death

(2011) John C. Reed et al.   Genetic Engineering & Biotechnology News

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of Oncology Drugs at the European Medicines Agency and US Food and Drug Administration: When Differences Have an Impact on Clinical Practice

(2011) Francesco Trotta et al.   JOURNAL OF CLINICAL ONCOLOGY

Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer

(2011) R. W. Humphrey et al.   JNCI-Journal of the National Cancer Institute

A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer

(2011) M. Hidalgo et al.   MOLECULAR CANCER THERAPEUTICS

The inverted pyramid of biomarker-driven trials

(2011) Ignacio Garrido-Laguna et al.   Nature Reviews Clinical Oncology

How were new medicines discovered?

(2011) David C. Swinney et al.   NATURE REVIEWS DRUG DISCOVERY

The productivity crisis in pharmaceutical R&D

(2011) Fabio Pammolli et al.   NATURE REVIEWS DRUG DISCOVERY

Genetically engineered murine models – Contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma

(2011) Louis Chesler et al.   SEMINARS IN CANCER BIOLOGY

Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs

(2010) J Cummings et al.   BRITISH JOURNAL OF CANCER

PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer

(2010) J. Dupont Jensen et al.   CLINICAL CANCER RESEARCH

The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee

(2010) L. Seymour et al.   CLINICAL CANCER RESEARCH

Preclinical drug development for childhood cancer

(2010) Lucas Moreno et al.   Expert Opinion on Drug Discovery

Adaptive design clinical trials: Methodology, challenges and prospect

(2010) Rajiv Mahajan et al.   INDIAN JOURNAL OF PHARMACOLOGY

Productivity Shortfalls in Drug Discovery: Contributions from the Preclinical Sciences?

(2010) M. Williams   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Anticancer drug development: the grand challenges

(2010) William N. Hait   NATURE REVIEWS DRUG DISCOVERY

How to improve R&D productivity: the pharmaceutical industry's grand challenge

(2010) Steven M. Paul et al.   NATURE REVIEWS DRUG DISCOVERY

Some drop-the-loser designs for monitoring multiple doses

(2010) Y. H. Joshua Chen et al.   STATISTICS IN MEDICINE

Randomized Phase II Designs

(2009) L. Rubinstein et al.   CLINICAL CANCER RESEARCH

Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies

(2009) Shivaani Kummar et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449

(2009) Charles M. Rudin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma

(2009) R. L. Yauch et al.   SCIENCE

Do molecularly targeted agents in oncology have reduced attrition rates?

(2008) Ian Walker et al.   NATURE REVIEWS DRUG DISCOVERY